Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibrobla...

Full description

Bibliographic Details
Main Authors: Tobias Puengel, Sander Lefere, Jana Hundertmark, Marlene Kohlhepp, Christian Penners, Frederique Van de Velde, Bruno Lapauw, Anne Hoorens, Lindsey Devisscher, Anja Geerts, Stephanie Boehm, Qihong Zhao, John Krupinski, Edgar D. Charles, Bradley Zinker, Frank Tacke
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:International Journal of Molecular Sciences
Subjects:
macrophages
monocytes
treatment strategies
chemokines
inflammation
fibroblast growth factor (FGF)
Online Access:https://www.mdpi.com/1422-0067/23/12/6696

Internet

https://www.mdpi.com/1422-0067/23/12/6696

Similar Items